Clinical Study

Ea8143- A Phase 3 Randomized Study Comparing Perioperative Nivolumab Vs. Observation In Patients With Localized Renal Cell Carcinoma Undergoing Nephrectomy (Prosper Rcc)

Posted Date: Jun 10, 2019

  • Investigator: Nilesh Patil
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

To compare recurrence-free survival (RFS) between patients with renal cell carcinoma randomly assigned to perioperative nivolumab in conjunction with radical or partial nephrectomy with patients randomized to surgery alone


To Be Eligible: Patients Must Be At Least 18 Years Of Age, No Evidence Of Distant Metastases, No Autoimmune Diseases, Uncontrolled Adrenal Insufficiency, Or Hepatitis Disease.


Renal Cancer, Kidney

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.